Cost-effectiveness of coronavirus disease 2019 vaccination in low-and middle-income countries

MJ Siedner, C Alba, KP Fitzmaurice… - The Journal of …, 2022 - academic.oup.com
Background Despite the advent of safe and effective coronavirus disease 2019 vaccines,
pervasive inequities in global vaccination persist. Methods We projected health benefits and …
被引用次数：30 相关文章

Cost-effectiveness of COVID-19 vaccination in low-and middle-income countries

MJ Siedner, C Alba, KP Fitzmaurice, RF Gilbert… - The Journal of … - ncbi.nlm.nih.gov
Background Despite the advent of safe and effective COVID-19 vaccines, pervasive
inequities in global vaccination persist. Methods We projected health benefits and donor …

Cost-effectiveness of Coronavirus Disease 2019 Vaccination in Low-and Middle-Income Countries

MJ Siedner, C Alba, KP Fitzmaurice… - The Journal of …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Despite the advent of safe and effective coronavirus disease 2019 vaccines,
pervasive inequities in global vaccination persist. Methods We projected health benefits and …

Cost-effectiveness of COVID-19 vaccination in low-and middle-income countries

MJ Siedner, C Alba, KP Fitzmaurice, RF Gilbert… - medRxiv, 2021 - medrxiv.org
Despite the advent of safe and highly effective COVID-19 vaccines–, pervasive inequities in
global distribution persist. In response, multinational partners have proposed programs to …

Cost-effectiveness of Coronavirus disease 2019 vaccination in low-and middle-income countries.

MJ Siedner, C Alba, KP Fitzmaurice, RF Gilbert… - 2022 - cabidigitallibrary.org
Background: Despite the advent of safe and effective coronavirus disease 2019 vaccines,
pervasive inequities in global vaccination persist. Methods: We projected health benefits …

Cost-effectiveness of Coronavirus Disease 2019 Vaccination in Low-and Middle-Income Countries.

MJ Siedner, C Alba, KP Fitzmaurice… - Journal of Infectious …, 2022 - search.ebscohost.com
Abstract < bold> Background: </bold> Despite the advent of safe and effective
coronavirus disease 2019 vaccines, pervasive inequities in global vaccination persist. < …

Cost-effectiveness of Coronavirus Disease 2019 Vaccination in Low-and Middle-Income Countries

MJ Siedner, C Alba, KP Fitzmaurice… - The Journal of …, 2022 - academic.oup.com
Background Despite the advent of safe and effective coronavirus disease 2019 vaccines,
pervasive inequities in global vaccination persist. Methods We projected health benefits and …
[PDF] researchgate.net

[PDF][PDF] Cost-effectiveness of COVID-19 vaccination in low-and middle-income countries

MJ Siedner, C Alba, KP Fitzmaurice, RF Gilbert… - 2022 - researchgate.net
We projected health benefits and donor costs of delivering vaccines for up to 60% of the 6
population in 91 low-and middle-income countries (LMICs). We modeled a highly …
[HTML] europepmc.org

[HTML][HTML] Cost-effectiveness of COVID-19 vaccination in low-and middle-income countries

MJ Siedner, C Alba, KP Fitzmaurice, RF Gilbert… - 2021 - europepmc.org
Despite the advent of safe and highly effective COVID-19 vaccines 1–4, pervasive inequities
in global distribution persist 5. In response, multinational partners have proposed programs …

Cost-effectiveness of Coronavirus Disease 2019 Vaccination in Low-and Middle-Income Countries.

MJ Siedner, C Alba, KP Fitzmaurice… - The Journal of …, 2022 - europepmc.org
Background Despite the advent of safe and effective coronavirus disease 2019 vaccines,
pervasive inequities in global vaccination persist. Methods We projected health benefits and …